COLINZPharmaceuticals
Colinz Laboratories Ltd — PE Ratio & Valuation Analysis
₹44.50
+0.00%
Current P/E39.55xPrice to earnings
Industry P/E31.77xSector average
4Y Avg P/E31.6x25.0% above avg
⚠️
24.5% Premium to Industry
COLINZ P/E 39.55x vs sector avg 31.77x
📊
Historical PE Ratio
| Year | EPS (₹) | Year-end Price | PE Ratio |
|---|---|---|---|
| 2025 | ₹1.97 | ₹54 | 27.2x |
| 2024 | ₹1.93 | ₹70 | 36.1x |
PE = Year-end closing price ÷ Diluted EPS. Source: NSE/BSE filings.
💡
Understanding Colinz Laboratories Ltd Valuation
Colinz Laboratories Ltd (COLINZ) currently trades at 39.55x earnings. The Pharmaceuticals sector average PE is 31.77x. COLINZ commands a premium, reflecting high growth expectations. Historically, COLINZ has traded at an average PE of 31.6x — it is currently above that level. Always evaluate PE alongside earnings growth (PEG ratio), return on equity, debt levels and business quality. A lower PE isn't always better. Educational data only — not investment advice.
ROE
5.43%
Dividend Yield
0.00%
More on Colinz Laboratories Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.